IL6 and coronary artery disorder: In patients with rheumatoid arthritis and no evidence of CAD/ischaemia, anakinra resulted in both an acute and sustained improvement in left ventricular function, endothelial function and coronary flow reserve with a reduction in IL-6 and endothelin-1, compared to placebo/prednisolone.